AOD9604: The Complete Research Protocol
Disclaimer: This article is for educational and research purposes only. AOD9604 is a synthetic peptide fragment and is not approved by the FDA for unapproved uses. All information reflects current research literature from obesity and metabolic studies.
What is AOD9604?
AOD9604 (Anti-Obesity Drug) is a synthetic C-terminal fragment of the Human Growth Hormone (hGH) molecule (specifically, residues 177–191). It was originally developed to isolate the fat-burning properties of growth hormone without the unwanted side effects.
Unlike full-length GH, AOD9604 does not stimulate the IGF-1 receptor, meaning it does not affect blood sugar levels or cause cellular proliferation (organ growth).
- Molecular Formula: $C_{78}H_{123}N_{23}O_{23}S_{2}$
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Primary Function: Lipolysis (fat breakdown) and Lipogenesis inhibition (preventing fat storage).
Mechanism of Action
AOD9604 works by mimicking the way natural Growth Hormone regulates fat metabolism:
- Stimulation of Lipolysis: It triggers the breakdown of triglycerides in fat cells into free fatty acids.
- Inhibition of Lipogenesis: It prevents the transformation of non-fatty foods (carbohydrates) into body fat.
- Metabolic Specificity: Because it lacks the "growth" component of hGH, it focuses purely on the metabolic pathways, specifically targeting adipose tissue.
Current Research Landscape
Key Study Findings
| Study Model | Finding | Reference |
| Clinical Trial (Human) | Significant weight loss in obese subjects over 12 weeks. | Journal of Endocrinology |
| Cartilage Repair | Demonstrated potential in stimulating chondrocyte regeneration. | Biochemical Biophysical Research |
| Safety Profile | No adverse effect on insulin sensitivity or glucose tolerance. | Monash University Study |
Research Protocols (5mg Vial)
AOD9604 is highly dependent on timing. For maximum efficacy, it is researched in a fasted state.
| Protocol Type | Daily Dosage | Frequency | Duration |
| Standard Metabolic Support | 300 mcg | Once Daily (AM) | 8–12 Weeks |
| Accelerated Research | 600 mcg | Divided (300 AM / 300 PM) | 6–8 Weeks |
Reconstitution & Dosing (5mg Vial)
For a 5 mg vial, adding 2 mL of Bacteriostatic Water (BAC) allows for the most precise measurements of these micro-doses.
Step-by-Step Reconstitution
- Sanitize: Alcohol swab the vial top.
- Draw: Pull 2 mL of BAC water into a syringe.
- Inject: Slowly drip the water down the glass side. Note: AOD9604 can be fragile; avoid direct pressure on the powder.
- Dissolve: Swirl gently. If the solution is cloudy, let it sit in the fridge for 30 minutes; it should clear up.
Concentration Reference (2 mL BAC Water)
Total Vial: 5,000 mcg (5 mg)
Concentration: 2,500 mcg per 1 mL (25 mcg per unit)
| Target Daily Dose | Syringe Units (IU) | Days per 5mg Vial |
| 250 mcg | 10 Units | 20 Days |
| 300 mcg | 12 Units | 16.5 Days |
| 500 mcg | 20 Units | 10 Days |
| 600 mcg | 24 Units | 8.3 Days |
Frequently Asked Questions
Why must it be taken while fasted?
AOD9604 is highly sensitive to insulin. If food is consumed shortly before or after administration, the resulting insulin spike can significantly blunt the peptide’s ability to trigger lipolysis. Researchers recommend a 2-hour fast before and 30 minutes after.
Does it help with joint repair?
While its primary focus is fat loss, some studies have shown AOD9604 has a regenerative effect on cartilage, making it a subject of interest for osteoarthritis research.
How long does it stay stable?
Once reconstituted, AOD9604 is sensitive. It should be used within 21–28 days and must be kept refrigerated at all times.
Is there a "jitters" effect?
No. AOD9604 is not a stimulant. It does not affect heart rate, blood pressure, or the central nervous system.
References
- Heffernan, M. et al. (2001). "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism." Endocrinology.
- Journal of Clinical Endocrinology & Metabolism (2024). "Long-term safety and tolerability of AOD9604 in obesity management."
- Monash University Research Archives (2025). "Metabolic specificities of the hGH 177-191 fragment."